Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (Nasdaq: FULC) announced the grant of an inducement award to newly appointed CFO Esther Rajavelu, approved by independent directors on January 3, 2022. The award includes a nonstatutory option to purchase 200,000 shares at an exercise price of $17.82, equal to the closing stock price on the grant date. The option has a ten-year term with 25% vesting after one year and subsequent quarterly vesting over three years, contingent on continued service. Fulcrum focuses on rare genetic diseases with lead programs targeting facioscapulohumeral muscular dystrophy and sickle cell disease.

Fulcrum Therapeutics (Nasdaq: FULC) announced that Bryan Stuart, President and CEO, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 p.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Fulcrum's website, with an archived replay accessible for 30 days following the event.

Fulcrum focuses on addressing rare diseases through innovative treatments like losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease, leveraging its proprietary product engine, FulcrumSeek™.

Fulcrum Therapeutics (NASDAQ: FULC) announced the appointment of Esther Rajavelu as Chief Financial Officer, effective immediately. Rajavelu brings nearly 20 years of experience in the life sciences sector, having held senior positions at UBS, Deutsche Bank, and Bank of America. Fulcrum is focusing on the development of therapies for rare genetic diseases, with promising clinical data for its products losmapimod and FTX-6058.

The company is preparing for significant growth, enhancing its leadership team with Rajavelu's strategic financial expertise.

Fulcrum Therapeutics (NASDAQ: FULC) reported promising results from its Phase 1 trial of FTX-6058, achieving a mean 5.6-fold and 6.2-fold induction of HBG mRNA at 20mg and 30mg doses, respectively, after 14 days. The treatment was well-tolerated, with no serious adverse events noted. New data indicates FTX-6058 effectively downregulates BCL11A and MYB, which are critical repressors of fetal hemoglobin. The company plans to start a Phase 1b trial for sickle cell disease by year-end 2021 and aims to submit an IND for other hemoglobinopathies.

Fulcrum Therapeutics (NASDAQ: FULC) has appointed Sonja L. Banks to its board of directors, effective December 8. Banks, currently the CEO of the International Dyslexia Association, brings 25 years of experience in patient advocacy and non-profit leadership. Her appointment aligns with Fulcrum's mission to advance therapies for rare genetic diseases like sickle cell disease and FSHD. Management believes Banks' expertise will enhance its programs aimed at improving patient outcomes in these areas.

Fulcrum Therapeutics (NASDAQ: FULC) provided a business update and reported Q3 2021 results, highlighting progress in clinical trials. The company is set to initiate a Phase 1b trial for FTX-6058 in sickle cell disease by year-end 2021, with an investigational new drug application expected for other hemoglobinopathies shortly after. Fulcrum raised $144.2 million in August 2021, securing its cash runway into 2024. Collaboration revenue rose to $4.9 million from $1.8 million YoY, while net loss increased to $20.7 million versus $19.0 million YoY. Key updates on losmapimod are anticipated in Q1 2022.

Fulcrum Therapeutics (Nasdaq: FULC) announced management participation in key investor conferences. These include the Credit Suisse 30th Annual Virtual Healthcare Conference on November 11, 2021 at 4:20pm ET, the Stifel Virtual Healthcare Conference on November 17, 2021 at 11:20am ET, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021. Live audio webcasts will be accessible via the Investor Relations section of the Fulcrum website, with archived replays available for 30 days.

Fulcrum Therapeutics (FULC) will release its Q3 2021 financial results on November 4, 2021, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET to discuss results and recent corporate developments. Fulcrum's focus is on patients with genetically defined rare diseases, with notable advancements including losmapimod in Phase 2 trials for facioscapulohumeral muscular dystrophy and FTX-6058 in Phase 1 trials for sickle cell disease and beta-thalassemia.

Fulcrum Therapeutics (Nasdaq: FULC) announced the approval of an inducement award for Naomi Aoki, the newly appointed SVP of Communications and Investor Relations, on September 10, 2021. The grant includes a nonstatutory stock option for 58,000 shares at an exercise price of $28.21, the closing price on September 30, 2021. The option has a ten-year term and vests over four years, promoting retention through gradual vesting. Fulcrum Therapeutics focuses on developing treatments for genetically defined rare diseases, advancing losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.